Checkpoint– tag –
-
FDA Grants Fast Track Designation to Multiple Oncology Drugs in May & June 2026, Including ADC for Metastatic Neuroendocrine Tumors
Oncology News Central USA Overview In May and June 2026, the U.S. FDA granted Fast Track designation to several novel oncology therapies, accelerating their development for serious conditions. Noteworthy designations include Zai Lab Limi... -
FDA Grants Breakthrough Therapy Designation to Merck’s Investigational KRAS G12C Inhibitor Calderasib (MK-1084) in Combination with KEYTRUDA for Metastatic NSCLC
BioSpace USA Overview Merck announced that its investigational oral KRAS G12C inhibitor, calderasib (MK-1084), in combination with KEYTRUDA® (pembrolizumab), received FDA Breakthrough Therapy Designation for newly diagnosed metastatic KR... -
Dana-Farber Cancer Institute Demonstrates Long-Term Efficacy of Sacituzumab Govitecan in Advanced Triple-Negative Breast Cancer
Dana-Farber Cancer Institute Newsroom USA Overview The antibody-drug conjugate (ADC), sacituzumab govitecan, demonstrated long-term benefits as a first-line treatment for advanced triple-negative breast cancer (TNBC) compared to standard...
12